Researchers from the Broad Institute and Jackson Laboratory demonstrated in a mouse model that prime editing can correct five genetic mutations causing alternating hemiplegia of childhood (AHC), a rare neurodevelopmental disorder. Treated mice showed substantial symptom reduction and significantly extended survival. This represents the first successful in vivo therapeutic prime editing for a neurological disease, opening avenues for treating other rare genetic disorders.